JP2017503753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503753A5 JP2017503753A5 JP2016532025A JP2016532025A JP2017503753A5 JP 2017503753 A5 JP2017503753 A5 JP 2017503753A5 JP 2016532025 A JP2016532025 A JP 2016532025A JP 2016532025 A JP2016532025 A JP 2016532025A JP 2017503753 A5 JP2017503753 A5 JP 2017503753A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 56
- 229910052799 carbon Inorganic materials 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 229940127121 immunoconjugate Drugs 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 5
- 125000001475 halogen functional group Chemical group 0.000 claims description 5
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000003700 epoxy group Chemical group 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- -1 C 1-6 -alkoxy Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000000034 method Methods 0.000 description 37
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 6
- 239000002184 metal Substances 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000006685 Achmatowicz rearrangement reaction Methods 0.000 description 2
- 238000005750 Corey-Bakshi-Shibata reduction reaction Methods 0.000 description 2
- 238000005865 alkene metathesis reaction Methods 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 238000005686 cross metathesis reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 2
- FSJSYDFBTIVUFD-XHTSQIMGSA-N (e)-4-hydroxypent-3-en-2-one;oxovanadium Chemical group [V]=O.C\C(O)=C/C(C)=O.C\C(O)=C/C(C)=O FSJSYDFBTIVUFD-XHTSQIMGSA-N 0.000 description 1
- 0 *C(C1)C(CC=C)OC(*)C1=O Chemical compound *C(C1)C(CC=C)OC(*)C1=O 0.000 description 1
- MJJYBIKJATXOSF-UHFFFAOYSA-N 2,3-dihydroxy-4-methylpent-3-enal Chemical compound CC(C)=C(O)C(O)C=O MJJYBIKJATXOSF-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- BDOLXPFAFMNDOK-UHFFFAOYSA-N oxazaborolidine Chemical compound B1CCON1 BDOLXPFAFMNDOK-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019125655A JP6929903B2 (ja) | 2013-11-19 | 2019-07-05 | 抗癌剤およびその調製方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906133P | 2013-11-19 | 2013-11-19 | |
| US61/906,133 | 2013-11-19 | ||
| PCT/US2014/066458 WO2015077370A1 (en) | 2013-11-19 | 2014-11-19 | Anti-cancer agents and preparation thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019125655A Division JP6929903B2 (ja) | 2013-11-19 | 2019-07-05 | 抗癌剤およびその調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503753A JP2017503753A (ja) | 2017-02-02 |
| JP2017503753A5 true JP2017503753A5 (Direct) | 2017-12-28 |
| JP6937578B2 JP6937578B2 (ja) | 2021-09-22 |
Family
ID=53180106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532025A Active JP6937578B2 (ja) | 2013-11-19 | 2014-11-19 | 抗癌剤およびその調製方法 |
| JP2019125655A Active JP6929903B2 (ja) | 2013-11-19 | 2019-07-05 | 抗癌剤およびその調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019125655A Active JP6929903B2 (ja) | 2013-11-19 | 2019-07-05 | 抗癌剤およびその調製方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10000505B2 (Direct) |
| EP (1) | EP3071563B1 (Direct) |
| JP (2) | JP6937578B2 (Direct) |
| KR (1) | KR102428737B1 (Direct) |
| CN (3) | CN113461705A (Direct) |
| AU (1) | AU2014353087B2 (Direct) |
| BR (1) | BR112016011430B1 (Direct) |
| CA (1) | CA2931111C (Direct) |
| CL (1) | CL2016001209A1 (Direct) |
| DK (1) | DK3071563T3 (Direct) |
| EA (1) | EA035262B1 (Direct) |
| ES (1) | ES2943711T3 (Direct) |
| FI (1) | FI3071563T3 (Direct) |
| IL (2) | IL282430B2 (Direct) |
| MX (1) | MX375896B (Direct) |
| MY (1) | MY189459A (Direct) |
| PE (1) | PE20161240A1 (Direct) |
| PH (2) | PH12021551085A1 (Direct) |
| PT (1) | PT3071563T (Direct) |
| WO (1) | WO2015077370A1 (Direct) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014353087B2 (en) * | 2013-11-19 | 2018-07-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| MX2018015269A (es) * | 2016-06-08 | 2019-09-18 | Univ Rice William M | Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos. |
| WO2018057897A1 (en) * | 2016-09-23 | 2018-03-29 | Ghosh Arun K | Anti-cancer agents and preparation thereof |
| IL302943A (en) | 2017-09-20 | 2023-07-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
| CN109020876A (zh) * | 2018-09-21 | 2018-12-18 | 大连理工大学 | 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法 |
| PE20211473A1 (es) | 2018-12-13 | 2021-08-05 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso |
| JP2023521135A (ja) * | 2020-04-09 | 2023-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | メアヤマイシン類似体および使用方法 |
| CN113563361B (zh) * | 2021-08-17 | 2022-05-20 | 浙江珲达生物科技有限公司 | 一种从伯克霍尔德菌发酵液提取fr901464的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US7825267B2 (en) * | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| EP2644204B1 (en) | 2008-03-18 | 2017-04-19 | Genentech, Inc. | Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab |
| AR080234A1 (es) * | 2010-02-25 | 2012-03-21 | Marrone Bio Innovations Inc | Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo |
| US20140221207A1 (en) * | 2011-08-27 | 2014-08-07 | Marrone Bio Innovations, Inc. | Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom- formulations and uses |
| CN105121421B (zh) * | 2012-11-05 | 2020-10-02 | 辉瑞公司 | 司普力西欧他汀类似物 |
| AU2014353087B2 (en) | 2013-11-19 | 2018-07-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2014
- 2014-11-19 AU AU2014353087A patent/AU2014353087B2/en active Active
- 2014-11-19 PT PT148632011T patent/PT3071563T/pt unknown
- 2014-11-19 JP JP2016532025A patent/JP6937578B2/ja active Active
- 2014-11-19 IL IL282430A patent/IL282430B2/en unknown
- 2014-11-19 WO PCT/US2014/066458 patent/WO2015077370A1/en not_active Ceased
- 2014-11-19 CN CN202110798232.6A patent/CN113461705A/zh active Pending
- 2014-11-19 CN CN201480070416.9A patent/CN105829299A/zh active Pending
- 2014-11-19 ES ES14863201T patent/ES2943711T3/es active Active
- 2014-11-19 EA EA201691010A patent/EA035262B1/ru not_active IP Right Cessation
- 2014-11-19 MX MX2016006591A patent/MX375896B/es active IP Right Grant
- 2014-11-19 CA CA2931111A patent/CA2931111C/en active Active
- 2014-11-19 PH PH1/2021/551085A patent/PH12021551085A1/en unknown
- 2014-11-19 MY MYPI2016000932A patent/MY189459A/en unknown
- 2014-11-19 KR KR1020167016232A patent/KR102428737B1/ko active Active
- 2014-11-19 US US15/038,027 patent/US10000505B2/en active Active
- 2014-11-19 CN CN202110798234.5A patent/CN113773333A/zh active Pending
- 2014-11-19 DK DK14863201.1T patent/DK3071563T3/da active
- 2014-11-19 BR BR112016011430-2A patent/BR112016011430B1/pt active IP Right Grant
- 2014-11-19 EP EP14863201.1A patent/EP3071563B1/en active Active
- 2014-11-19 FI FIEP14863201.1T patent/FI3071563T3/fi active
- 2014-11-19 PE PE2016000653A patent/PE20161240A1/es unknown
-
2016
- 2016-05-15 IL IL245637A patent/IL245637B/en active IP Right Grant
- 2016-05-19 CL CL2016001209A patent/CL2016001209A1/es unknown
- 2016-05-19 PH PH12016500924A patent/PH12016500924A1/en unknown
-
2019
- 2019-07-05 JP JP2019125655A patent/JP6929903B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503753A5 (Direct) | ||
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| JP2012530779A5 (Direct) | ||
| RU2012101947A (ru) | Способы лечения и профилактики усталости | |
| JP2010138190A5 (Direct) | ||
| MX2013012588A (es) | Inhibidores de cinasa. | |
| CA2637765A1 (en) | Benzamide and heteroarene derivatives | |
| EA202092671A1 (ru) | Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания | |
| RU2005109913A (ru) | Азабициклоалкильные эфиры и их применение в качестве агонистов альфа7-nachr | |
| JP2020514316A5 (Direct) | ||
| JP2015535247A5 (Direct) | ||
| JP6174627B2 (ja) | （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の製造方法 | |
| JP2017524742A (ja) | テトラヒドロキノリン誘導体の調製のための合成中間体の調製方法 | |
| JP2017525765A (ja) | 新規イミノニトリル誘導体 | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| EP4585269A3 (en) | Methods for cancer therapy | |
| NO20061319L (no) | 5-arylpyrimidiner som anticancer legemidler | |
| CN103965175B (zh) | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 | |
| WO2008124823A1 (en) | Method of treating melanoma | |
| GEAP202516737A (en) | Compounds for treating cancer | |
| JP2017516829A5 (Direct) | ||
| JP2013525290A5 (Direct) | ||
| JP2018140987A5 (Direct) |